Back to Authors

Weinshenker, Brian G

0000-0001-5806-6203

Mayo Clinic

From the Department of Neurology (S.S.S., M.B., D.T., B.G.W., S.J.P., E.P.F., M.T.B., J.J.C.), and Center for Multiple Sclerosis and Autoimmune Neurology (S.S.S., M.B., D.M.W., B.G.W., S.J.P., E.P.F., J.J.C.), Mayo Clinic, Rochester, MN; Department of Neur

Citations 140

Randomized, comparative study of interferon β-1a treatment regimens in MS

Neurology | May 13, 2012 | Volume: 59 | Issue: 10 | Pages: 1496-1506

10.1212/01.wnl.0000034080.43681.da | PMID 12451188

Pregnancy

Neurology | March 8, 2012 | Volume: 78 | Issue: 12 | Pages: 846-848

10.1212/wnl.0b013e31824d1858 | PMID 22402865

Solitary sclerosis

Neurology | February 9, 2012 | Volume: 78 | Issue: 8 | Pages: 540-544

10.1212/wnl.0b013e318247cc8c | PMID 22323754

Evidence-based guideline: Clinical evaluation and treatment of transverse myelitis: [RETIRED]

Neurology | December 8, 2011 | Volume: 77 | Issue: 24 | Pages: 2128-2134

10.1212/wnl.0b013e31823dc535 | PMID 22156988

The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease

Multiple Sclerosis Journal | December 6, 2011 | Volume: 18 | Issue: 1 | Pages: 5-10

10.1177/1352458511431077 | PMID 22146604

Neuromyelitis optica (NMO) and NMO spectrum disorders (NMOSD) are associated with autoantibodies that target aquaporin-4 and, in many cases, multiple other autoantibodies, including antinuclear antibody and antibodies to extractable nuclear antigens. The clinical syndromes that define NMO and NMOSD, especially longitudinally extensive transverse myelitis and optic neuritis, can also occur in the context of established rheumatologic diseases such as systemic lupus erythematosus and Sjögren syndrome and other organ-specific autoimmune diseases. These observations raise questions fundamental to both clinical practice and etiologic research. For example, they could suggest that NMO is one manifestation of a genetic tendency toward humoral autoimmunity. Alternatively, they might indicate that NMO is a central nervous system complication of a multisystem rheumatologic disease. We describe the historical background of this controversy, summarize the current evidence that addresses NMO–systemic autoimmunity relationships, and discuss the practical implications for clinical management.
Syndrome of inappropriate antidiuresis may herald or accompany neuromyelitis optica

Neurology | October 14, 2011 | Volume: 77 | Issue: 17 | Pages: 1644-1646

10.1212/wnl.0b013e3182343377 | PMID 21998320

Genetic analysis of aquaporin-4 in neuromyelitis optica

Neurology | September 8, 2011 | Volume: 77 | Issue: 12 | Pages: 1149-1155

10.1212/wnl.0b013e31822f045b | PMID 21900637

Does detection of anti-AQP4 antibodies trump clinical criteria for neuromyelitis optica?

Neurology | August 4, 2011 | Volume: 77 | Issue: 9 | Pages: 812-813

10.1212/wnl.0b013e31822b012a | PMID 21813783

Azathioprine

Neurology | August 4, 2011 | Volume: 77 | Issue: 7 | Pages: 659-666

10.1212/wnl.0b013e31822a2780 | PMID 21813788

A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis

Neurology | June 14, 2011 | Volume: 64 | Issue: 7 | Pages: 1267-1269

10.1212/01.wnl.0000156803.23698.9a | PMID 15824361